Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc., a clinical-stage biotech company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, c… Read more
Duality Biotherapeutics, Inc. (4ZB) - Total Assets
Latest total assets as of June 2025: €4.18 Billion EUR
Based on the latest financial reports, Duality Biotherapeutics, Inc. (4ZB) holds total assets worth €4.18 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Duality Biotherapeutics, Inc. - Total Assets Trend (2022–2024)
This chart illustrates how Duality Biotherapeutics, Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Duality Biotherapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Duality Biotherapeutics, Inc.'s total assets of €4.18 Billion consist of 91.4% current assets and 8.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 57.8% |
| Accounts Receivable | €379.02 Million | 18.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €46.24 Million | 2.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how Duality Biotherapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Duality Biotherapeutics, Inc.'s current assets represent 91.4% of total assets in 2024, an increase from 87.3% in 2022.
- Cash Position: Cash and equivalents constituted 57.8% of total assets in 2024, down from 81.1% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 11.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 18.1% of total assets.
Duality Biotherapeutics, Inc. Competitors by Total Assets
Key competitors of Duality Biotherapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Duality Biotherapeutics, Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Duality Biotherapeutics, Inc. generates 0.93x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Duality Biotherapeutics, Inc. is currently not profitable relative to its asset base.
Duality Biotherapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.73 | 0.50 | 0.50 |
| Quick Ratio | 4.73 | 0.50 | 0.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.22 Billion | € -1.64 Billion | € -1.64 Billion |
Duality Biotherapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Duality Biotherapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.69 |
| Asset Growth Rate (YoY) | 39.4% |
| Total Assets | €2.09 Billion |
| Market Capitalization | $1.45 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Duality Biotherapeutics, Inc.'s assets below their book value (0.69 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Duality Biotherapeutics, Inc.'s assets grew by 39.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Duality Biotherapeutics, Inc. (2022–2024)
The table below shows the annual total assets of Duality Biotherapeutics, Inc. from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €2.09 Billion | +39.36% |
| 2023-12-31 | €1.50 Billion | +223.44% |
| 2022-12-31 | €463.74 Million | -- |